GeneFab

GeneFab is at the Keystone Symposia for Cancer Immunotherapy and Immune Cell Therapies in Banff, Canada.?Meet Duncan Liew, PhD and Russell Gordley to brainstorm the use of #SynBio for your research projects and clinical programs ?? We're eager to partner on cutting-edge solutions to advance cancer and autoimmune disease treatments. Let's connect! ?? #ImmuneCellTherapies #GeneFab #CGT #CellTherapy #GeneTherapy #Partnership #Innovation #Banff ??

?? We are excited to announce that Philip Lee, our CEO, will be speaking at the 10th Innate Killer Conference on March 5th at 12 PM! ?? ?? In his session, Philip will delve into the key capabilities of GeneFab that can support cell and gene therapy (CGT) startups as they move into early and late-phase trials. He will share insights on: ?? Strategic partnership to reduce manufacturing costs ?? The importance of having an experienced CDMO partner like GeneFab for speed-to-market If you're a CGT startup eager to advance your innovation to the clinic, this talk is not to be missed! Join us to discover how GeneFab can be your essential partner on the journey to success. Let’s unlock the potential of gene therapy together! ?? #InnateKillerConference #GeneFab #CGT #Biotech #Startups #Manufacturing #ProductDevelopment

?? We are thrilled to announce that our Director of Technical Development, Wesley Gorman, will be a featured speaker at the 10th Innate Killer Conference! ?? Wesley will be sharing invaluable insights on creating a standardized approach for tech transfer that is tailored to customer needs and aligns with the complexities of early phase product life cycle management. Key highlights of his session include: ?? Case studies on the CAR-NK process and analytical development?? ?? Best practices for preparing processes and methods for a smooth transfer into cGMP environments? If you are looking to accelerate your therapeutic development into early phase trials, you won't want to miss this talk! Join us to gain practical strategies that can help streamline your product development journey. Let’s navigate the path from bench to bedside together! ??? #InnateKillerConference #TechTransfer #CARNK #Biotech #Startups #ProductDevelopment #cGMP

Congratulations to the entire Senti Team! The entire GeneFab team is here as your partner as you bring these lifesaving and first-in-class cell therapies to AML patients. We are honored to be your partner, and look forward to helping at every step to commercialization. #AML #CellTherapy

GeneFab is approaching our 1 year anniversary, and we thank all of our clients and employees that helped us be very successful in our first year. GeneFab is officially on the map helping the innovative Cell Therapy innovators. We are drug manufacturers that are drug makers, having spent 7 years as a biotech developing innovative drugs. Now we have already signed multiple clients, and you can access this team to advance your programs. GeneFab is the genetic and synthetic engineering company focused on outsourced R&D for drug design (synthetic biology foundry) as well as manufacturing of Cell Therapies (all types). - Synthetic Biology Design Services: https://lnkd.in/gbuwjET8 - Cell Therapy Platforms: https://lnkd.in/gNQZxYZj - End-to-end Clinical and Commercial manufacturing including Cell Banking, Viral Vector (Gamma Retro, Lentivirus, others), and Rapid Tech Transfer to cGMP manufacturing: https://lnkd.in/gufrhgfj

As the leading manufacturer of NK Cell Therapies we are always pleased to read and share work to target diseases done by colleagues around the globe. This one comes from Southern California. https://lnkd.in/gCDiHH-S GeneFab is the genetic and synthetic engineering company focused on outsourced R&D for drug design (synthetic biology foundry) as well as manufacturing of Cell Therapies (all types). Synthetic Biology Design Services: https://lnkd.in/gbuwjET8 Cell Therapy Platforms: https://lnkd.in/gNQZxYZj All Services for end-to-end Clinical and Commercial manufacturing including Cell Banking, Viral Vector (Gamma Retro, Lentivirus, others), and Rapid Tech Transfer to manufacturing: https://lnkd.in/gufrhgfj

A personal congratulations to Senti and CIRM from GeneFab's CEO Philip Lee: "Congrats Senti and CIRM! This is an excellent example of how breakthrough innovation in cell therapies can be directly accelerated by CIRM to impact patients and strengthen California biotech."

Congrats to our partners Senti Biosciences on the commencement of their Phase 1 clinical trial! Proud to be collaborating with you on manufacturing SENTI-202, a potential cell therapy for treating relapsed/refractory?hematologic malignancies including acute myeloid leukemia (AML). #syntheticbiology

Join us at #ASGCT24 for our second presentation where we’ll be showcasing the development of highly potent promoters that activate gene expression specifically in macrophages in the anti-inflammatory state to enable control of macrophage phenotype. Looking forward to seeing you there or at Booth #1641!